Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Krystal Biotech, Inc.NASDAQ: KRYS
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables grows, but more slowly than its trailing trend
Q2 FY2026 accounts receivables of $11.97M (cash outflow) rose 46.4% year over year, behind the +233.4% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 5.7% of revenue in FY2025, down 15.9 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +46.4% toward the trailing-twelve-month pace of +233.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (22.12M) USD
- Year-over-year change
- +64.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.12M) | +64.7% |
| FY2024 | 2024-12-31 | (62.71M) | -49.2% |
| FY2023 | 2023-12-31 | (42.04M) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's LTM Jun 2026 accounts receivables of $27.35M is the largest of the 6 companies compared; the peer median is $0.
- Its year-over-year change of +233.4% is the 2nd highest of 4, against a peer median of -178.8%.
- Accounts receivables amounts to 6.2% of revenue for KRYS, versus a peer median of 16.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $27.35M | +233.4% | — | 6.2% | |
| LTM Mar 2026 | $13.03M | -178.8% | — | 16.3% | |
| LTM Mar 2026 | $9.02M | +328.9% | — | 10.3% | |
| LTM Mar 2026 | $5.09M | -985.6% | — | 35.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding KRYS) | $0 | -178.8% | — | 16.3% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (69.57M) | (139.98M) | 10.93M | 89.16M | 204.83M |
| Depreciation & Amortization | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (22.85M) |
| Stock-Based Compensation | 15.32M | 33.23M | 39.93M | 49.13M | 54.51M |
| Change in Working Capital | 2.05M | 2.81M | (37.88M) | (14.46M) | (36.42M) |
| Accounts Receivables | 0 | 0 | (42.04M) | (62.71M) | (22.12M) |
| Inventory | 0 | 0 | (4.48M) | (11.91M) | (6.29M) |
| Accounts Payables | 712K | (1.25M) | (101K) | 1.01M | 826K |
| Other Working Capital | 1.34M | 4.07M | 8.73M | 59.15M | (8.84M) |
| Other Non-Cash Items | 1.49M | (690K) | (106.79M) | (7.12M) | (5.77M) |
| Operating Cash Flow | (47.94M) | (100.57M) | (88.8M) | 123.42M | 200.87M |
| Capital Expenditures | (68.34M) | (52.98M) | (11.8M) | (4.24M) | (11.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 435K |
| Purchases of Investments | (190.46M) | (318.78M) | (508.78M) | (457.74M) | (422.54M) |
| Sales of Investments | 32.03M | 257.68M | 503.21M | 298.54M | 375.64M |
| Other Investing Activities | 0 | 0 | 100M | 0 | 0 |
| Investing Cash Flow | (226.77M) | (114.08M) | 82.64M | (163.44M) | (58.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 355.65M | 36M | 203.5M | 32.4M | 22.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.96M) | (649K) | (749K) | (5.39M) | (13.96M) |
| Financing Cash Flow | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M |
| Effect of Forex Changes | 0 | (41K) | (156K) | (458K) | 286K |
| Net Change in Cash | 72.98M | (179.35M) | 196.43M | (13.46M) | 151.44M |
| Free Cash Flow | (116.27M) | (153.55M) | (100.6M) | 119.18M | 188.91M |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.